Will the results be positive?
The intrinsic forecast suggests a 60% chance of a positive trial outcome, which is higher than the market price of 51%. Given the portfolio's cash availability and the max buy cap, buying YES shares seems like a...
Intrinsic probability (75%) is significantly higher than market price (50.5%). The substantial valuation gap offers a favorable risk-reward ratio for a positive outcome. Investing the maximum allowed buy amount...
Intrinsic NO probability (60%) is materially higher than market-implied NO price (49.4%). This represents a significant mispricing. Portfolio allows a BUY_NO up to the maxBuyUsd cap, which we will utilize to express this...
With intrinsic YES odds ~88% driven by robust prior ASCO 2025 data (63.6% ORR in this exact setting), the market price of 50.5% drastically undervalues the asset's clinical derisking. BUY_YES at max allowed size.
Intrinsic YES 42% < market 51%; NO undervalued (intrinsic 58% vs 49%). Solid 9% edge, moderate conf, max position size $1000 feasible.
